These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 11379482)
1. Hyperhomocysteinemia in end-stage renal failure. Kes P Acta Med Croatica; 2000; 54(4-5):175-81. PubMed ID: 11379482 [TBL] [Abstract][Full Text] [Related]
2. Hyperhomocysteinemia in end stage renal disease: is treatment necessary? Snavely J Nephrol Nurs J; 2002 Apr; 29(2):155-60; quiz 161-2. PubMed ID: 11997950 [TBL] [Abstract][Full Text] [Related]
3. Homocysteine-lowering is not a primary target for cardiovascular disease prevention in chronic kidney disease patients. Suliman ME; Lindholm B; Bárány P; Qureshi AR; Stenvinkel P Semin Dial; 2007; 20(6):523-9. PubMed ID: 17991198 [TBL] [Abstract][Full Text] [Related]
4. Hyperhomocysteinemia and its relationship to cardiovascular disease in ESRD: influence of hypoalbuminemia, malnutrition, inflammation, and diabetes mellitus. Suliman ME; Stenvinkel P; Bárány P; Heimbürger O; Anderstam B; Lindholm B Am J Kidney Dis; 2003 Mar; 41(3 Suppl 1):S89-95. PubMed ID: 12612961 [TBL] [Abstract][Full Text] [Related]
5. Clinical use and rational management of homocysteine, folic acid, and B vitamins in cardiovascular and thrombotic diseases. Stanger O; Herrmann W; Pietrzik K; Fowler B; Geisel J; Dierkes J; Weger M Z Kardiol; 2004 Jun; 93(6):439-53. PubMed ID: 15252738 [TBL] [Abstract][Full Text] [Related]
7. [Characteristics of hyperhomocysteinemia in dialysis patients]. Lovcić V; Kes P; Reiner Z Acta Med Croatica; 2006; 60(1):21-6. PubMed ID: 16802568 [TBL] [Abstract][Full Text] [Related]
8. Plasma homocysteine levels and cardiovascular mortality in patients with end-stage renal disease. Buccianti G; Baragetti I; Bamonti F; Furiani S; Dorighet V; Patrosso C J Nephrol; 2004; 17(3):405-10. PubMed ID: 15365961 [TBL] [Abstract][Full Text] [Related]
9. It is important to lower homocysteine in dialysis patients. Zoccali C; Mallamaci F; Tripepi G Semin Dial; 2007; 20(6):530-3. PubMed ID: 17991199 [TBL] [Abstract][Full Text] [Related]
10. Homocysteinemia correlates with plasma thiol redox status in patients with end-stage renal disease. Palleschi S; De Angelis S; Rossi B; Diana L; Papa V; Severini G; Splendiani G Nephron Clin Pract; 2008; 108(2):c106-12. PubMed ID: 18212512 [TBL] [Abstract][Full Text] [Related]
11. [Hyperhomocysteinemia as a vascular risk factor in chronic hemodialysis patients]. Trimarchi H; Young P; Díaz ML; Schropp J; Forrester M; Freixas E Medicina (B Aires); 2005; 65(6):513-7. PubMed ID: 16433478 [TBL] [Abstract][Full Text] [Related]
12. Homocysteine as a risk factor for cardiovascular disease in patients treated by dialysis: a meta-analysis. Heinz J; Kropf S; Luley C; Dierkes J Am J Kidney Dis; 2009 Sep; 54(3):478-89. PubMed ID: 19359080 [TBL] [Abstract][Full Text] [Related]
14. [Hyperhomocysteinemia and advancement of atherosclerosis in patients with chronic renal failure on maintenance hemodialysis]. Sydor A; Drozdz M; Kraśniak A; Miłkowski A; Chmiel G; Małczak J; Zabawa-Hołyś S; Moskal K; Podwysocki A; Szmigielski M; Czarnecka D; Gozdecka H; Kowalczyk-Michałek M; Szczeklik A; Wiecek A; Sułowicz W Przegl Lek; 2002; 59(12):962-7. PubMed ID: 12731367 [TBL] [Abstract][Full Text] [Related]
15. Elevated homocysteine levels in patients with end-stage renal disease. Nair AP; Nemirovsky D; Kim M; Geer EB; Farkouh ME; Winston J; Halperin JL; Robbins MJ Mt Sinai J Med; 2005 Nov; 72(6):365-73. PubMed ID: 16358160 [TBL] [Abstract][Full Text] [Related]
16. Folic acid 5 or 15 mg/d similarly reduces plasma homocysteine in patients with moderate-advanced chronic renal failure. Bernasconi AR; Liste A; Del Pino N; Rosa Diez GJ; Heguilén RM Nephrology (Carlton); 2006 Apr; 11(2):137-41. PubMed ID: 16669976 [TBL] [Abstract][Full Text] [Related]
17. [The treatment of hyperhomocysteinemia in patients on dialysis: folic acid or the high-flow polysulphonic membrane?]. Lovcić V; Kes P; Zeljko R; Kusec V Acta Med Croatica; 2006 Jun; 60(3):201-8. PubMed ID: 16933832 [TBL] [Abstract][Full Text] [Related]
18. Homocysteine, a new cardiovascular risk factor, is also a powerful uremic toxin. Perna AF; Castaldo P; Ingrosso D; De Santo NG J Nephrol; 1999; 12(4):230-40. PubMed ID: 10493566 [TBL] [Abstract][Full Text] [Related]
19. Vitamin B12 decreases, but does not normalize, homocysteine and methylmalonic acid in end-stage renal disease: a link with glycine metabolism and possible explanation of hyperhomocysteinemia in end-stage renal disease. Hyndman ME; Manns BJ; Snyder FF; Bridge PJ; Scott-Douglas NW; Fung E; Parsons HG Metabolism; 2003 Feb; 52(2):168-72. PubMed ID: 12601627 [TBL] [Abstract][Full Text] [Related]
20. [Frequency of hyperhomocysteinemia in hemodialysis patients with folic acid supplementation]. Kárpáti I; Balla J; Szóke G; Bereczky Z; Páll D; Ben T; Toma K; Katona E; Mohácsi A; Paragh G; Varga Z; Kakuk G; Muszbek L Orv Hetil; 2002 Jul; 143(27):1635-40. PubMed ID: 12180000 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]